News

UCB0599 reduces inflammation, improves coordination in mice

The experimental oral therapy UCB0599 — now in clinical trials — improves motor coordination and reduces inflammation and levels of the disease-related protein alpha-synuclein in a mouse model of Parkinson’s disease. “This comprehensive package of [Parkinson’s]-relevant improvements supports the rationale of directly targeting misfolded [alpha-synuclein] with the small molecule minzasolmin…

MJFF, Quansys to develop immunoassays for Parkinson’s

Quansys Biosciences and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to develop tests that can help monitor Parkinson’s disease progression and evaluate treatment effectiveness in clinical trials. The partnership builds on the company’s expertise in immunoassays, a type of test that uses…

UT Health San Antonio among new Comprehensive Care Centers

The Parkinson’s Foundation has designated the University of Texas Health Science Center at San Antonio (UT Health San Antonio) a Comprehensive Care Center, making it the first such center in Texas and expanding the organization’s Global Care Network. The designation heightens access to specialized multidisciplinary care…

Blood pressure medications don’t affect Parkinson’s progression

Medications that lower blood pressure don’t appear to influence the progression of Parkinson’s disease, a study reports. The study, “Antihypertensive drugs may not delay the symptom progression of Parkinson’s disease: A 2-year follow-up study,” was published in Heliyon. The symptoms of Parkinson’s disease are caused…

Parkinson’s Foundation awards $1M in community grants

From yoga therapy in Miami, Florida to a Ruston, Louisiana music and movement program, the Parkinson’s Foundation has awarded nearly $1 million in 2023 community grants for Parkinson’s disease programs that span 34 U.S. states and include international centers in Canada and Germany. The foundation’s community…